A detailed smoking history and determination of <i>MYC</i> status predict response to checkpoint inhibitors in advanced non-small cell lung cancer.

Transl Lung Cancer Res · 2020 · PMC7082292 · PMID 32206553

Europe PMC DOI

hedged sentences

0.0970

closest p · 1.9× alpha

0.0970

boldest claim

The sentences

showed a trendP=0.097so close (0.05 < p ≤ 0.1)

In comparison, a current or former smoking status showed a trend with response to immunotherapy (0% vs. 23.8%; P=0.097).

also in 53,322 other papers

marginally significantno p-value reported

Unlike the other mutations, multivariate analysis shows that MYC amplification remains marginally significant in predicting response when controlling for patient age and smoking status with an OR of 3.85.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.